CD47抗体;CD47 Antibody—艾普蒂

+ +

•  

   

     Black line: Control Antigen (100 ng);Purple line: Antigen (10ng); Blue line: Antigen (50 ng); Red line:Antigen (100 ng)    

  
  

•  

   

     Western blot analysis using CD47 mouse mAb against Jurkat (1), MOLT4 (2), HL-60 (3), Raji (4), Ramos (5), and HEK293 (6) cell lysate.    

  
  

•  

   

     Immunofluorescence analysis of Hela cells using CD47 mouse mAb (green). Blue: DRAQ5 fluorescent DNA dye. Red: Actin filaments have been labeled with Alexa Fluor- 555 phalloidin. Secondary antibody from Fisher (Cat#: 35503)    

  
  

•  

   

     Flow cytometric analysis of Hela cells using CD47 mouse mAb (green) and negative control (red).    

  
  

•  

   

     Flow cytometric analysis of Jurkat cells using CD47 mouse mAb (green) and negative control (red).    

  
  

•  

   

     Flow cytometric analysis of K562 cells using CD47 mouse mAb (green) and negative control (red).    

  
  

•  

   

     Immunohistochemical analysis of paraffin-embedded human bladder cancer tissues using CD47 mouse mAb with DAB staining.    

  
  

CD47. a transmembrane glycoprotein widely expressed on normal cells, functions as a "don't eat me" signal by binding to signal regulatory protein alpha (SIRPα) on macrophages and other myeloid cells. This interaction inhibits phagocytosis, enabling healthy cells to evade immune surveillance. However, many cancers exploit this pathway by overexpressing CD47 to avoid macrophage-mediated clearance, making it a promising therapeutic target.

CD47-blocking antibodies aim to disrupt the CD47-SIRPα axis, thereby enhancing phagocytosis of cancer cells. Early studies demonstrated their potential in hematologic malignancies and solid tumors, often in combination with tumor-opsonizing antibodies (e.g., rituximab) to synergistically enhance macrophage activity. Challenges include on-target toxicity, as CD47 is expressed on erythrocytes and platelets, leading to anemia and thrombocytopenia in clinical trials. Next-generation agents, such as magrolimab (anti-CD47) with engineered Fc domains or SIRPα-Fc fusion proteins, aim to improve safety profiles by minimizing erythrocyte binding.

Research also explores CD47's role in immune checkpoint regulation, tumor stemness, and therapeutic resistance. Combination strategies with chemotherapy, radiation, or immune checkpoint inhibitors (e.g., anti-PD-1/PD-L1) are under investigation to overcome resistance mechanisms. Despite setbacks in some trials, CD47 remains a key focus in immuno-oncology, with ongoing efforts to refine targeting approaches and identify predictive biomarkers for patient stratification.